Mihael Polymeropoulos, Vanda Pharmaceuticals CEO
Vanda buys J&J's multiple sclerosis drug Ponvory for $100M
Vanda Pharmaceuticals has paid $100 million to Actelion Pharmaceuticals, a Johnson & Johnson company, for the US and Canada rights to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
